Myocardial Infarction

Subscribe to Selected New Research on Myocardial Infarction

44751 relevant articles (2308 outcomes, 7885 trials/studies) found for this Disease

Description: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).

Also Known As:

Myocardial Infarct; Infarct, Myocardial; Infarction, Myocardial; Infarctions, Myocardial; Infarcts, Myocardial; Myocardial Infarctions; Myocardial Infarcts

Relationship Network

Disease Context: Research Results

Cardiovascular Diseases: 20552

Heart Diseases: 13044

Myocardial Ischemia: 13523

Myocardial Infarction: 44751

Cardiogenic Shock: 2013

Myocardial Stunning: 843

Vascular Diseases: 7633

Myocardial Ischemia: 13523

Myocardial Infarction: 44751

Cardiogenic Shock: 2013

Myocardial Stunning: 843

No-Reflow Phenomenon: 244

Related Diseases

1.	Stroke (Strokes)
2.	Heart Failure
3.	Unstable Angina
4.	Ischemia
5.	Hypertension (High Blood Pressure)

Experts

1.	Stone, Gregg W: 54 articles (07/2008 - 02/2002)
2.	Gibson, C Michael: 53 articles (09/2008 - 01/2002)
3.	Braunwald, Eugene: 50 articles (09/2008 - 02/2002)
4.	Murphy, Sabina A: 48 articles (09/2008 - 01/2002)
5.	Grines, Cindy L: 44 articles (07/2008 - 03/2002)
6.	Cannon, Christopher P: 42 articles (09/2008 - 07/2002)
7.	Antman, Elliott M: 42 articles (05/2008 - 02/2002)
8.	Suryapranata, Harry: 40 articles (08/2008 - 06/2002)
9.	Zijlstra, Felix: 38 articles (05/2008 - 06/2002)
10.	Ottervanger, Jan Paul: 37 articles (08/2008 - 03/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Myocardial Infarction:

1.	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/01/1996 - "Women who benefited the most from aspirin therapy were older, diabetic, symptomatic, or had a previous myocardial infarction. " 08/01/2004 - "BACKGROUND: A meta-analysis of randomized trials has shown a significant reduction of mortality rate in patients receiving aspirin for secondary prevention after acute myocardial infarction (AMI). " 11/01/2001 - "At the start of the eighties, in the wake of the good results obtained with aspirin in secondary prevention, two studies were launched aimed at testing the effect of aspirin on the primary prevention of myocardial infarction. " 02/15/1980 - "The Aspirin Myocardial Infarction Study (AMIS) was a National Heart, Lung and Blood Institute-sponsored, multicenter, randomized, double-blind, and placebo-controlled trial designed to test whether the regular administration of aspirin to men and women who had experienced at least one documented myocardial infarction (MI) would result in a significant reduction in total mortality over a three-year period. " 07/01/1999 - "NO-aspirins and the combination of an NO-donor with aspirin promise to be beneficial in the early stages of myocardial infarction. " Order ALL the reference details at left...
2.	Streptokinase FDA Link 08/01/1981 - "The use of streptokinase (avelisine) in patients with acute myocardial infarction was accompanied by defibrinisation of the blood, by marked decrease of the aggregation facility of formed elements of the blood and its viscosity. " 01/01/2000 - "Efficacy of rapid infusion of streptokinase in patients with acute myocardial infarction." 03/01/1996 - "Thrombolytic treatment of the acute myocardial infarction with intravenous streptokinase is safe and effective, and may successfully be carried out also in district hospitals in which cardiac catheterization and cardiosurgery are inaccessible." 07/25/1994 - "In conclusion: patients treated with intravenous streptokinase for acute myocardial infarction reach both higher heart rates and rate-pressure products at maximum workload than their controls thus indicating that the beneficial effects of thrombolysis after acute myocardial infarction are reflected in an improved heart rate response during exercise." 01/01/1988 - "To evaluate the efficacy of intravenous streptokinase in acute myocardial infarction (AMI) 108 patients received a high-dose (1.5 million units), short-term infusion (60 minutes) within 6 hours after onset of symptoms, followed by anticoagulation. " Order ALL the reference details at left...
3.	Heparin (Liquaemin)FDA LinkGeneric 11/01/2000 - "A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction." 03/10/2009 - "BACKGROUND: Although weight-based nomograms have improved the efficacy and safety of dosing unfractionated heparin in ST-segment elevation myocardial infarction, achieving therapeutic anticoagulation in practice remains challenging. " 09/01/2001 - "The authors conclude that the use of low dose heparin appears effective and safe in cases without acute myocardial infarction. " 04/01/1990 - "SK and t-PA with or without post-thrombolytic heparin treatment appear equally effective and safe for use in routine conditions care, in all patients with acute myocardial infarction (AMI)." 11/01/1998 - "BACKGROUND: The safety and efficacy of bedside monitors of activated partial thromboplastin time (aPTT) have not been examined in a large population receiving intravenous heparin after thrombolytic treatment for acute myocardial infarction. " Order ALL the reference details at left...
4.	Tissue Plasminogen Activator (Alteplase)FDA Link 06/01/1992 - "In this Bolus Dose-Escalation Study of Tissue-Type Plasminogen Activator (BEST), the efficacy of 3 different doses of a single rapid intravenous bolus injection of t-PA (dute-plase, Wellcome Foundation, London) in inducing coronary patency (Thrombolysis In Myocardial Infarction perfusion grade 2 or 3) in 64 patients with acute myocardial infarction presenting less than 6 hours after onset of symptoms was investigated. " 07/01/1995 - "Ideally, patients should receive alteplase as soon as possible after the onset of symptoms of acute myocardial infarction and, while therapy is most beneficial when administered early, survival is improved when the drug is administered up to 12 hours after symptom onset. " 01/01/1994 - "Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction." 12/01/1990 - "This study assesses whether administration of recombinant tissue-type plasminogen activator (rt-PA) up to 8 hours after onset of symptoms of acute myocardial infarction (AMI) may result in a significant improvement in left ventricular function. " 04/01/1990 - "Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: results of a multicenter randomized trial of two dosage regimens." Order ALL the reference details at left...
5.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 08/01/1996 - "Most clinical trials of angiotensin converting enzyme inhibitors after myocardial infarction have shown an improved outcome with reduction of morbidity and mortality. " 06/01/2000 - "BACKGROUND: ACE inhibitors have shown beneficial results in several studies after myocardial infarction (MI). " 03/01/2000 - "The results of major clinical trials leave us in no doubt that ACE inhibitors are useful in the treatment of patients after myocardial infarction. " 07/06/1998 - "The SAVE trial specifically evaluated the effects on post-myocardial infarction mortality and remodeling and found that ACE inhibitors were effective in reducing both. " 01/01/2008 - "Angiotensin Converting Enzyme inhibitors (ACE-I) are effective in reducing mortality and preventing left ventricular (LV) function deterioration after myocardial infarction. " Order ALL the reference details at left...
6.	Fibrinolytic Agents (Antithrombotic Agents)IBA 07/05/2005 - "Recent studies have indicated that a selective inhibitor of TAFIa could enhance the efficacy of existing thrombolytic agents for the treatment of acute myocardial infarction, one of the most prevalent forms of heart attacks. " 01/01/2004 - "This review examines the most significant trends in the pharmacologic therapy of ST-segment elevation myocardial infarction since the publication of these early studies: the development of fibrinolytic drugs with improved clot selectivity and improved pharmacokinetic profiles that simplify administration, making ED or even prehospital thrombolysis more practical. " 01/01/1984 - "The development of newer specific thrombolytic agents with low toxicity, without antigenicity, and available for rapid parenteral administration holds much promise for the treatment of acute myocardial infarction in the future." 10/01/2004 - "BACKGROUND: Patients in clinical trials of fibrinolytic agents have been shown to be younger, less often female, and to have lower risk characteristics and a better outcome compared with unselected patients with ST-elevation myocardial infarction. " 03/01/1997 - "Early and sustained flow of grade 3 according to Thrombolysis in Myocardial infarction (TIMI) criteria and reocclusion rates are the key measures that define the physiologic efficacy of thrombolytic agents in the treatment of acute myocardial infarction. " Order ALL the reference details at left...
7.	glucuronyl glucosamine glycan sulfate (Vessel)IBA 05/01/2009 - "All the treated vessels (100%) were successfully re-canalized, Trials In Myocardial Infarction (TIMI) score of 3. At 90-day follow-up, of the 5 patients treated, 2 had modified Rankin score (mRS) of < 2. This small series shows the safety and efficacy of the Penumbra System in the thrombolysis of large vessel occlusive disease." 05/01/1993 - "Different thrombolytic regimens for acute myocardial infarction proved to be equally effective in large scale mortality trials despite significant differences in their efficacy with respect to early infarct-related vessel patency as shown in smaller angiographic trials. " 05/01/2009 - "Infarct size, vessel formation and blood perfusion were significantly improved 28 days after myocardial infarction (MI) in FGFR2-Tg, compared with wild-type mice. " 06/06/2006 - "At one-year clinical follow-up (100% of patients), the event-free survival (freedom from death, myocardial infarction, and target vessel revascularization) was significantly improved in the SES group (88% vs. 69%; p < 0.004) as the result of a lower requirement for target vessel revascularization (11% vs. 30%; p < 0.003). " 03/01/2004 - "Statistically significant improvement was noted in late angiographic restenosis (34.7% vs. 76.5%, p <0.0001), target vessel revascularization (14.9% vs. 60.6), and major adverse cardiac events (i.e., death, myocardial infarction, or total vessel revascularization) (17.9% vs. 64.9%, p <0.0001) at 6 months in reference to the nonradiation group. " Order ALL the reference details at left...
8.	clopidogrel (Plavix)FDA LinkGeneric 07/04/2006 - "Clopidogrel was also associated with a significant reduction in the odds of an in-hospital death or myocardial infarction in patients who achieved partial (OR 0.30, p = 0.003) or complete STRes at 90 min (OR 0.49, p = 0.056), whereas clinical benefit was not apparent in patients who had no STRes (OR 0.98, p = 0.95) (p for interaction = 0.027). " 01/01/2006 - "After ACS with non-ST-elevation myocardial infarction the combined therapy with ASA and clopidogrel gives a better outcome than ASA alone. " 09/14/2005 - "OBJECTIVE: To determine if clopidogrel pretreatment before PCI in patients with recent ST-segment elevation myocardial infarction (STEMI) is superior to clopidogrel treatment initiated at the time of PCI in preventing major adverse cardiovascular events. " 05/01/2008 - "Clopidogrel (Plavix), a platelet aggregation inhibitor, has been shown to be effective in certain patients undergoing percutaneous coronary interventions, but its use in patients with acute myocardial infarction who receive a fibrinolytic strategy instead has been controversial. " 04/14/2009 - "OBJECTIVES: The aim of this study was to examine the interaction between cigarette smoking and the clinical efficacy of clopidogrel in ST-segment elevation myocardial infarction (STEMI). " Order ALL the reference details at left...
9.	Glycoproteins (Glycoprotein)IBA 04/01/2009 - "Several clinical trials have shown that antagonists of the glycoprotein IIb/IIIa receptor decreased the incidence of death, nonfatal myocardial infarction, and the need for urgent revascularization when administered immediately before or during the 24- to 48-hour period after percutaneous coronary intervention (PCI). " 09/16/2003 - "BACKGROUND: Trials of platelet glycoprotein IIb/IIIa inhibitors as adjuncts to primary percutaneous coronary intervention for acute myocardial infarction (MI) have shown improved early clinical and angiographic outcomes with treatment. " 04/01/2007 - "OBJECTIVE: We reviewed the literature and performed a meta-analysis comparing the safety and efficacy of adjunctive use of reduced-dose thrombolytics and glycoprotein (Gp) IIbIIIa inhibitors to the sole use of Gp IIbIIIa inhibitors before percutaneous coronary intervention (PCI) in patients presenting with acute ST-segment elevation myocardial infarction (STEMI). " 01/01/2004 - "PlA polymorphism of the glycoprotein IIIa and efficacy of reperfusion therapy in patients with acute myocardial infarction." 01/01/2009 - "Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network." Order ALL the reference details at left...
10.	Captopril (Capoten)FDA LinkGeneric 04/01/1993 - "Captopril has a favorable effect on the dysfunctioning myocardium after myocardial infarction inasmuch as the ischemic burden is reduced, the working capacity is increased, dilation of the left ventricle is prevented, and systolic function is improved." 02/15/1996 - "CONCLUSION: The treatment with captopril after acute myocardial infarction is not only a clinically efficacious treatment, but also cost-effective in patients after acute myocardial infarction." 04/13/1991 - "Thus early treatment with captopril is effective in preventing the ventricular dilatation that can occur after Q wave myocardial infarction." 01/01/1989 - "The just published study of the efficacy of captopril in preventing the progression of left ventricular dilatation in patients with a recent anterior, transmural myocardial infarction supports this view. " 08/01/2009 - "1. Recently, we demonstrated that oral captopril treatment improved diastolic function and attenuated cardiac remodelling after myocardial infarction (MI) in rats. " Order ALL the reference details at left...

Therapies and Procedures

1.	Thrombolytic Therapy 05/25/2005 - "This article examines thrombolytic therapy, the first-line treatment for patients presenting with acute myocardial infarction in most UK hospitals. " 12/01/1994 - "Thrombolytic therapy has been proven to be highly effective and safe in patients presenting with acute myocardial infarction. " 07/15/1994 - "CONCLUSIONS: RV involvement during acute inferior myocardial infarction, accurately diagnosed by ST-segment elevation in V4R, is a strong, independent parameter for mortality and major in-hospital complications and may help to identify patients who will benefit most from thrombolytic therapy. " 05/01/1996 - "Multiple clinical trials have proven that thrombolytic therapy is an effective treatment for acute myocardial infarction. " 04/17/2001 - "These important findings provide evidence of a direct link between endogenous fibrinolysis, endothelial dysfunction, and atherothrombosis in the coronary circulation and may explain the greater efficacy of thrombolytic therapy for myocardial infarction in cigarette smokers." Order ALL the reference details at left...
2.	Angioplasty (Angioplasties) 09/01/2008 - "BACKGROUND: Primary angioplasty is the most effective treatment of ST-segment elevation acute myocardial infarction (STEMI). " 11/01/2005 - "BACKGROUND: Primary angioplasty is the best treatment of acute myocardial infarction but fails to achieve adequate myocardial reperfusion in 25% to 30% of patients, despite TIMI grade 3 flow. " 05/01/2001 - "A mechanical approach to reperfusion using direct coronary angioplasty is now an established and effective treatment for acute myocardial infarction, but it is not immediately available at most community hospitals. " 06/01/1997 - "RESULTS: Most reported series have shown that direct angioplasty is a feasible and safe option for the management of acute myocardial infarction. " 01/01/1996 - "[Is immediate coronary angioplasty the best treatment in acute myocardial infarction?]" Order ALL the reference details at left...
3.	Percutaneous Coronary Transluminal Angioplasty (PTCA) 10/01/1993 - "It is well known that rapid myocardial reperfusion, obtained using thrombolysis and/or PTCA, continues to be the best treatment for evolving myocardial infarction. " 08/07/2001 - "BACKGROUND: Whereas survival after lytic therapy for myocardial infarction is strongly dependent on early administration, it is unknown whether the otherwise excellent outcomes in patients undergoing primary PTCA for acute myocardial infarction, in whom TIMI-3 flow rates of >90% may be achieved, can be further improved by early reperfusion. " 11/01/1998 - "Improvement in exercise capacity is an important clinical effect of percutaneous transluminal coronary angioplasty (PTCA), and was assessed in patients with and without previous myocardial infarction (MI) undergoing PTCA. " 02/01/1996 - "PTCA (percutaneous transluminal coronary angioplasty) has proved to be safe and effective treatment for myocardial infarction which, as compared with thrombolytic treatment, yields more complete revascularisation, better coronary blood flow, reduced mortality, lower relapse rates, and shorter treatment times. " 04/01/2005 - "Six months after myocardial infarction LVEF was significantly greater and LVED, LVES volumes smaller in patients treated with primary PTCA in comparison to patients treated with thrombolysis. " Order ALL the reference details at left...
4.	Stents 08/01/2002 - "Since 1995, when the very good results of the stent implantation in patients with acute myocardial infarction were published, there has been a general trend to more stenting also in the Czech Republic. " 04/01/2006 - "The cause of the arrest was acute myocardial infarction which was treated successfully with percutaneous cardiac intervention (PCI) and a stent placement. " 09/01/2009 - "Over the last 20 years, the outcome of ACS and PCI patients has considerably improved, thanks to better pharmacologic environment, urgent reperfusion in STEMI (ST elevation myocardial infarction), timely revascularisation in non-ST elevation ACS (NSTEACS) and improved PCI techniques, particularly widespread use of stents. " 12/01/2006 - "It is likely that this benefit will translate into improved 5-year outcomes, with reduction in need for repeat revascularization in many patients and possibly reduced incidence of myocardial infarction and death, especially in diabetic patients, in whom the risk for occlusive restenosis and 5-year death and myocardial infarction rates are known to be higher after bare-metal stents. " 05/01/2006 - "It is likely that this benefit will translate into improved 5-year outcomes, with reduction in need for repeat revascularization in many patients and possibly reduced incidence of myocardial infarction and death, especially in diabetic patients, in whom the risk for occlusive restenosis and 5-year death and myocardial infarction rates are known to be higher after bare-metal stents. " Order ALL the reference details at left...
5.	Transplantation (Transplant Recipients) 12/01/2009 - "Engraftments of SKMs with knockdowned miRNA-181a similarly improved cardiac function as SKM transplantation but significantly decreased the arrhythmogenic effect of SKM transplantation in rats with experimental myocardial infarction." 02/01/2007 - "Transplantation of AM gene-engineered MSCs improved cardiac function after myocardial infarction significantly more than MSCs alone. " 02/01/2003 - "Hemodynamic and echocardiographic data showed that embryonic stem cell transplantation significantly improved ventricular function relative to the myocardial infarction plus medium control group. " 10/01/2007 - "CONCLUSION: This study demonstrates that sustained bFGF delivery enhances the angiogenic efficacy of CBMNC transplantation in rat myocardial infarction models." 04/01/2004 - "OBJECTIVES: To prove whether intramyocardial transplantation of combined skeletal myoblasts (SM) and mononuclear bone marrow stem cells is superior to the isolated transplantation of these cell types after myocardial infarction in rats. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Myocardial Infarction

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2308 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>